Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Evaluation of 177 Lu and 47 Sc Picaga-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry

Journal Article · · Molecular Pharmaceutics
 [1];  [2];  [2];  [3];  [2];  [1]
  1. Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, New York 11794, United States
  2. Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
  3. Brookhaven National Laboratory, Upton, New York 11973, United States; Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York 11794, United States
+ Show Author Affiliations

Not provided.

Research Organization:
Univ. of Alabama, Birmingham, AL (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
DOE Contract Number:
SC0020197
OSTI ID:
1978167
Journal Information:
Molecular Pharmaceutics, Vol. 18, Issue 12; ISSN 1543-8384
Publisher:
American Chemical Society (ACS)
Country of Publication:
United States
Language:
English

References (34)

Production and Use of the First-Row Transition Metal PET Radionuclides 43,44 Sc, 52 Mn, and 45 Ti September 2018
47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes June 2017
Matching chelators to radiometals for radiopharmaceuticals January 2014
H 4 octapa-Trastuzumab: Versatile Acyclic Chelate System for 111 In and 177 Lu Imaging and Therapy August 2013
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study September 2011
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors January 2017
Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications April 2015
Lutetium-labelled peptides for therapy of neuroendocrine tumours February 2012
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography January 2011
AAZTA5/AAZTA5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu August 2019
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy January 2016
DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy July 1997
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer January 2004
Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand April 2009
68 Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging March 2012
Clinical Translation and First In-Human Use of [ 44 Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer January 2017
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer March 2017
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 January 2017
Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44 January 2020
Homologous Structural, Chemical, and Biological Behavior of Sc and Lu Complexes of the Picaga Bifunctional Chelator: Toward Development of Matched Theranostic Pairs for Radiopharmaceutical Applications December 2020
DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177 Lu-Radionuclide Tumor Therapy in Mice December 2012
Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets July 2020
Preclinical Evaluation of 203/212 Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer June 2019
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer April 2015
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer April 2015
Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications January 2020
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors March 2016
Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile February 2018
Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for 64 Cu-Based PET Imaging October 2018
Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy April 2018
Development of an in vitro model for assessing the in vivo stability of lanthanide chelates February 2001
Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for 64 Cu/ 67 Cu-Based Theranostics in Prostate Cancer April 2020
Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent June 2018
Enhancing Treatment Efficacy of 177 Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies September 2018

Similar Records

Related Subjects

Research & Experimental Medicine
Pharmacology & Pharmacy